Daniel O’Dea becomes hope in the corona crisis

New York, Daniel O’Dea, head of the US biotech group Gilead His drug Remdesivir could help fight the coronavirus.

Daniel O’Dea said it’s antiviral drug Remdesivir is a beacon of hope on the fight against the coronavirus.

two weeks ago O’Dea traveled to Washington with other U.S pharmaceutical CEOs and biotech industries.

US President Donald Trump actually wanted to request the reduce pharmaceutical high prices.
during the meeting, the trump realized that one participant of the meeting could help contain the corona crisis.
when O’Dea told, his company already has a cure for the coronavirus Covid-19 disease, Trump said, “This is all very exciting,”

Is there a coronavirus vaccine?

It’s a global corona crisis that O’Dea, says into the spotlight in a very short of time, just one year after taking office at the California biotech company Gilead.

Gilead’s drug Remdesivir is currently in its second phase of clinical testing originally developed to fight against Ebola.

However, it only had a dubious effect and used more successfully for Sars’ respiratory disease.

Similar to various AIDS drugs, redeliver blocks an enzyme that viruses need to reproduce.

According to Gilead, in animal experiments, the substance has shown a relatively broad antiviral effect, including against the pathogens of Mars infections related to Sars.

US researchers have seen that as an indication the drug could also act against the causative agent of the coronavirus.

In China, the United States and Europe, hospitals are now testing the drug on volunteers with Covid-19.

There is a hope that if we use it early that can aware course of the disease O’Dea had nothing to do with the development of the drug and 56 years old could benefit from it.

Because he knows how to successfully run a pharmaceutical company as a graduate biologist.
he worked at the Swiss pharmaceutical and diagnostics group Roche, for several decades before moving to Gilead During his time at Roche.

He completed his MBA at the renowned Columbia University and later on, he became CEO of the pharmaceutical division and it’s so important for the Swiss promising products from other manufacturers.

Read Also: Coronavirus Q&A

For the native Texan of Irish descent, the current attention is rather unusual.

Conclusion

Finally, the company had to struggle with declining sales of hepatitis and AIDS medication, also because of the competition in this area’s depressed prices.

That’s why O’Dea looking out for other manufacturers with promising products.

In early March, the Gilead chief had paid nearly $5 billion to take over the young biotech company Forty-Seven, which is working on promoting blood cancer drugs.

Last year, they spent about $4 billion on the partnership with Belgian biotech company Galapagos and acquire 22 percent stakes.

Galapagos Gilead’s sales are approximately $20 billion annually.

The global corona crisis could mean Gilead’s biggest sales surge.

a few years ago at a dinner of the “Irish America” company O’Dea said that my Irish ancestors are a professional and personal motivation for me.